[1] Waks AG, Winer EP.Breast cancer treatment[J]. JAMA,2019,321(3):316.
[2] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials[J]. Lancet,2011,378(9793):771-784.
[3] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials[J]. Lancet,2015,386(10001):1341-1352.
[4] Pan H, Gray R, Braybrooke J, et al.20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med,2017,377(19):1836-1846.
[5] Burstein HJ, Temin S, Anderson H, et al.Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update[J]. J Clin Oncol,2014,32(21):2255-2269.
[6] Davies C, Pan H, Godwin J, et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet,2013,381(9869):805-816.
[7] Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[J]. J Clin Oncol,31,2013(suppl;abstr5).
[8] Tormey DC, Gray R, Falkson HC.Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer[J]. J Natl Cancer Inst,1996,88(24):1828-1833.
[9] Stewart HJ, Prescott RJ, Forrest AP.Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years[J]. J Natl Cancer Inst,2001,93(6):456-462.
[10] Fisher B, Dignam J, Bryant J, et al.Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J]. J Natl Cancer Inst,2001,93(9):684-690.
[11] Al-Mubarak M, Tibau A, Templeton AJ, et al.Extended adjuvant tamoxifen for early breast cancer: a meta-analysis[J]. PLoS One,2014,9(2):e88238.
[12] Bartlett J, Sgroi D, Treuner K, et al. Breast Cancer Index predicts benefit of extended endocrine therapy in HR+ breast cancers treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial[J]. Ann Oncol,2019.pii:mdz289.
[13] Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2009,pii: mdz189. doi: 10.1093/annonc/mdz189.
[14] NCCN. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 2.2019) [DB/OL]. [2019-08-02].http://www.nccn.org.
[15] Goss PE, Ingle JN, Martino S, et al.Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17[J]. J Natl Cancer Inst,2005,97(17):1262-1271.
[16] Goss PE, Ingle JN, Pater JL, et al.Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen[J]. J Clin Oncol,2008,26(12):1948-1955.
[17] Mamounas EP, Jeong JH, Wickerham DL, et al.Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial[J]. J Clin Oncol,2008,26(12):1965-1971.
[18] Jakesz R, Greil R, Gnant M, et al.Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a[J]. J Natl Cancer Inst,2007,99(24):1845-1853.
[19] Gray R. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women[EB/OL]. Presented at2018 SABCS, December 4-8, 2018; San Antonio, Abstract GS3-03.[2019-08-02]. https://www.abstracts2view.com/sabcs/view.php?nu=SABCS18L_1589
[20] Sgroi DC, Carney E, Zarrella E, et al.Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker[J]. J Natl Cancer Inst,2013,105(14):1036-1042.
[21] Burstein HJ, Lacchetti C, Anderson H, et al.Adjuvant endocrine therapy for women with hormone receptor-po-sitive breast cancer: ASCO clinical practice guideline focused update[J]. J Clin Oncol,2019,37(5):423-438.
[22] Goss PE, Ingle JN, Pritchard KI, et al.Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med,2016,375(3):209-219.
[23] Mamounas EP, Bandos H, Lembersky BC, et al.Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol,2019,20(1): 88-99
[24] Ohtani S, Iijima K, Higaki K, et al. A prospective randomized multi-center open-label phase Ⅲ trial of exten-ding aromatase-inhibitor adjuvant therapy to 10 years-results from1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS)[EB/OL]. Presented at 2018 SABCS, December 4-8, 2018; San Antonio, Abstract GS3-04. [2019-08-02].https://www.abstracts2view.com/sabcs/view.php?nu=SABCS 18L_415
[25] Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine the-rapy for early breast cancer; results of the IDEAL Trial (BOOG 2006-05)[J]. J Natl Cancer Inst,2018,110(1).doi: 10.1093/jnci/djx134.
[26] Gnant M, Steger G, Greil R, et al. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial[EB/OL]. Presented at2017 San Antonio Breast Cancer Symposium, December 5-9, 2017; San Antonio, TX. Abstract GS3-01. [2019-08-02].https://www.abstracts2view.com/sabcs17/view.php?nu=SABCS17L_676.
[27] Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial[J]. Lancet Oncol,2017,18(11):1502-1511.
[28] Mastro LD, Mansutti M, Bisagni G, et al. Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase Ⅲ study of Gruppo Italiano Mammella(GIM)[J]. J Clin Oncol,37,2019(suppl;abstr504).
[29] Goldvaser H, Barnes TA, Seruga B, et al.Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis[J]. J Natl Cancer Inst,2018,110(1):31-39.
[30] Dowsett M, Sestak I, Regan MM, et al.Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy: CTS5[J]. J Clin Oncol,2018,36(19):1941-1948.
[31] Richman J, Ring AE, Dowsett M, et al. Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer[J]. J Clin Oncol,37,2019(suppl;abstr514).
[32] Sestak I, Buus R, Cuzick J.Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer a secondary analysis of a rando-mized clinical trial[J]. JAMA Oncol,2018,4(4):545-553.
[33] Zhang Y, Schroeder BE, Jerevall PL, et al.A novel Breast Cancer Index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes[J]. Clin Cancer Res,2017,23(23):7217-7224.
[34] Curtis C, Shah SP, Chin SF, et al.The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups[J]. Nature,2012,486(7403):346-352.
[35] Rueda OM, Sammut SJ, Seoane JA, et al.Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups[J]. Nature,2019,567(7748):399-404.
